A Phase II, Single Centre, Open-label, Randomized Study to Investigate Meningococcal Serogroup A, C, W-135 and Y Saccharide Specific B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants.
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2014
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Novartis
- 31 Aug 2018 Biomarkers information updated
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database).
- 12 Jul 2011 EudraCT reports trial staus is recruiting.